[go: up one dir, main page]

SG10201604560TA - Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition - Google Patents

Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Info

Publication number
SG10201604560TA
SG10201604560TA SG10201604560TA SG10201604560TA SG10201604560TA SG 10201604560T A SG10201604560T A SG 10201604560TA SG 10201604560T A SG10201604560T A SG 10201604560TA SG 10201604560T A SG10201604560T A SG 10201604560TA SG 10201604560T A SG10201604560T A SG 10201604560TA
Authority
SG
Singapore
Prior art keywords
compositions
preventing
conditions
methods
extracellular matrix
Prior art date
Application number
SG10201604560TA
Inventor
Cynthia Lander
Colleen Brophy
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of SG10201604560TA publication Critical patent/SG10201604560TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG10201604560TA 2011-04-12 2012-04-12 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition SG10201604560TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161474370P 2011-04-12 2011-04-12

Publications (1)

Publication Number Publication Date
SG10201604560TA true SG10201604560TA (en) 2016-07-28

Family

ID=47006527

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201604560TA SG10201604560TA (en) 2011-04-12 2012-04-12 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
SG2013075031A SG194135A1 (en) 2011-04-12 2012-04-12 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013075031A SG194135A1 (en) 2011-04-12 2012-04-12 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Country Status (15)

Country Link
US (2) US9642888B2 (en)
EP (1) EP2696888B1 (en)
JP (1) JP6031510B2 (en)
KR (1) KR101862291B1 (en)
CN (3) CN108014340A (en)
AU (1) AU2012242768B2 (en)
BR (1) BR112013026313A8 (en)
CA (2) CA2832910C (en)
DK (1) DK2696888T3 (en)
ES (1) ES2711670T3 (en)
HK (1) HK1255005A1 (en)
MX (1) MX359516B (en)
RU (1) RU2620066C2 (en)
SG (2) SG10201604560TA (en)
WO (1) WO2012142320A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1976828T (en) 2005-12-29 2017-04-25 Celtaxsys, Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
CA2689296C (en) 2007-01-10 2015-11-17 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
ES2547229T3 (en) 2007-08-07 2015-10-02 Purdue Research Foundation Kinase inhibitors and uses thereof
US9327008B2 (en) * 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US9890195B2 (en) * 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US20110288036A1 (en) * 2010-05-24 2011-11-24 Cynthia Lander Methods for Treating or Preventing Vascular Graft Failure
SG10201604560TA (en) 2011-04-12 2016-07-28 Moerae Matrix Inc Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US9890200B2 (en) * 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
FR2976587B1 (en) * 2011-06-20 2015-04-03 Basf Beauty Care Solutions F IN VITRO DOSING METHOD BY IMMUNOLOGICAL TECHNIQUE
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
EP3278805A1 (en) * 2012-10-31 2018-02-07 Galecto Biotech AB Diagnosing pulmonary fibrosis
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
JP6527851B2 (en) 2013-03-12 2019-06-05 セルタクシス，インコーポレイテッド Method of inhibiting leukotriene A4 hydrolase
BR112015022226A2 (en) 2013-03-14 2017-07-18 Celtaxsys Inc leukotriene a4 hydrolase inhibitors
AU2013388034B2 (en) 2013-04-30 2019-08-15 Aspeya US Inc. Dry powder formulations and methods of use
US20150258192A1 (en) * 2014-03-14 2015-09-17 Colleen Brophy Compositions and methods for preventing or treating chronic lung allograft dysfunction (clad) and idiopathic pulmonary fibrosis (ipf)
US10336788B2 (en) * 2014-04-17 2019-07-02 Moerae Matrix, Inc. Inhibition of cardiac fibrosis in myocardial infarction
RU2017121090A (en) 2014-11-17 2018-12-20 Мори Матрикс, Инк. COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF DISEASES, STATE OR PROCESSES CHARACTERIZED BY ABERRANT PROLIFERATION OF FIBROBLASTS AND ACCUMULATION OF EXTRACELLULAR MATRIX
HK1246807A1 (en) * 2015-01-08 2018-09-14 Moerae Matrix, Inc. Formulation of mk2 inhibitor peptides
KR20170125090A (en) * 2015-03-12 2017-11-13 모레 매트릭스 인코포레이티드 Use of an MK2 inhibitor peptide-containing composition for treating non-cell lung cancer
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CA3076353A1 (en) 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
CN107987128B (en) * 2017-11-17 2019-06-11 广东医科大学 A functional polypeptide and its application in the preparation of a drug for preventing and treating pulmonary fibrosis
CN112437663A (en) * 2018-05-17 2021-03-02 开动疗法公司 Treatment of idiopathic pulmonary fibrosis with a beta-type glycogen synthase kinase 3 inhibitor
US10898484B2 (en) 2018-05-31 2021-01-26 Celltaxis, Llc Method of reducing pulmonary exacerbations in respiratory disease patients
CN110108883A (en) * 2018-10-27 2019-08-09 广州呼吸健康研究院 It is combined for screening with the marker of the accurate medicine of MSC of target treatment ARDS patient
CN109406795A (en) * 2018-11-20 2019-03-01 昆明医科大学 A kind of serum molecules diagnostic marker of light-duty brain trauma and application
WO2021040673A1 (en) * 2019-08-26 2021-03-04 Alain Martin Methods for the treatment of chronic hypoxemia and inhibiting lung fibrosis in patients with pulmonary fibrosis with and without copd
USD958124S1 (en) 2019-12-16 2022-07-19 Samsung Electronics Co., Ltd. Television receiver
USD978094S1 (en) 2019-12-27 2023-02-14 Samsung Electronics Co., Ltd. Television receiver
US11744807B2 (en) * 2020-01-17 2023-09-05 Sami-Sabinsa Group Limited Therapeutic compositions and methods for pulmonary fibrosis
CN112386682B (en) * 2020-02-12 2022-12-06 王斌 Application of fibronectin in the preparation of drugs for the treatment of novel coronavirus pneumonia
WO2021202031A1 (en) * 2020-03-30 2021-10-07 Figene, Llc Peptides and adjuvants for augmentation of fibroblast therapy for coronavirus
EP4142751A4 (en) * 2020-04-01 2025-01-08 Figene, LLC FIBROBLAST-INDUCED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME
WO2021214767A1 (en) * 2020-04-21 2021-10-28 Remodeless Cv Ltd Novel threrapy for acute damage to lung tissue
USD989726S1 (en) 2020-12-03 2023-06-20 Samsung Electronics Co., Ltd. Television receiver
USD989017S1 (en) 2020-12-03 2023-06-13 Samsung Electronics Co., Ltd. Television receiver
US20230416352A1 (en) * 2020-12-03 2023-12-28 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-connective tissue growth factor antibody
WO2022147172A1 (en) * 2020-12-30 2022-07-07 Briotech, Inc. Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions
US20220296645A1 (en) * 2021-03-22 2022-09-22 Spiritus Therapeutics, Inc. Diagnostic and therapeutic uses of compositions comprising purified, enriched potent exosomes containing disease-based and therapy based signature cargo
CN113440431A (en) * 2021-08-02 2021-09-28 山西锦波生物医药股份有限公司 Application of recombinant III-type humanized collagen in scalp care and scalp care product containing same
CN116262112A (en) * 2021-12-14 2023-06-16 南京安吉生物科技有限公司 Fusion polypeptide preparation for aerosol inhalation and preparation method and application thereof
AU2023207395A1 (en) 2022-01-14 2024-07-11 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof
CN114522221B (en) * 2022-02-28 2024-04-19 中国人民解放军陆军特色医学中心 Application of secreted protein CTGF in preparation of medicine for treating acute lung injury
WO2023178169A2 (en) * 2022-03-15 2023-09-21 Anemoi Biotech Holdings, Inc. Compositions and methods for treating the pathophysiology of severe viral infection
CN116421704A (en) * 2023-02-20 2023-07-14 成都佩德生物医药有限公司 Application of polypeptide PD-DP-005 in preparing medicament for treating lung diseases and medicament thereof
CN116789751B (en) * 2023-08-22 2023-11-17 中国农业大学 Polypeptide for preventing and/or treating fibrosis diseases and application thereof
CN117577330B (en) * 2024-01-15 2024-04-02 北京大学 Device and storage medium for predicting liver fibrosis degree of nonalcoholic fatty liver disease

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
ES286422Y (en) 1982-10-08 1986-09-16 Glaxo Group Limited DEVICE FOR ADMINISTERING MEDICINES TO PATIENTS
SE8603252L (en) 1985-07-30 1987-01-31 Glaxo Group Ltd DEVICE FOR SUPPLYING MEDICINE TO PATIENTS
JPH05963A (en) 1990-04-13 1993-01-08 Toray Ind Inc Polypeptide composition
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
DE69333955D1 (en) 1992-04-24 2006-02-02 Stanford Res Inst Int TARGETING HOMOLOGOUS SEQUENCES IN EUKARYOTIC CELLS
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
JP3585238B2 (en) 1993-12-09 2004-11-04 トーマス ジェファーソン ユニバーシティー Compounds and methods for site-directed mutagenesis in eukaryotic cells
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
ES2261195T3 (en) 1999-04-05 2006-11-16 Mannkind Corporation METHOD OF FORMATION OF FINE PARTICLES.
ES2569916T3 (en) 1999-06-29 2016-05-13 Mannkind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
KR20110017465A (en) 2002-04-25 2011-02-21 더 스크립스 리서치 인스티튜트 Treatment and prevention of pulmonary disease symptoms
BR0312785A (en) * 2002-07-19 2005-08-30 Abbott Biotech Ltd Treatment of Tnf-related disorders (alpha)
WO2005051093A1 (en) * 2003-11-25 2005-06-09 Hill's Pet Nutrition, Inc. Composition for animal consumption and method for reducing map kinase activity
WO2005110410A2 (en) * 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
ES2385934T3 (en) 2004-08-20 2012-08-03 Mannkind Corporation CATALYSIS OF THE SYNTHESIS OF DICETOPIPERAZINA.
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diketopiperazine salts for drug delivery
KR20070057829A (en) 2004-08-23 2007-06-07 맨카인드 코포레이션 Lung Delivery of Inhibitors of Phosphodiesterase 5
CN101227918A (en) * 2005-04-29 2008-07-23 加州大学评议会 Peptides and peptidomimetics for the treatment of pathologies characterized by inflammatory responses
US7799344B2 (en) 2005-09-14 2010-09-21 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US8039431B2 (en) 2006-02-22 2011-10-18 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
TW200817047A (en) * 2006-04-03 2008-04-16 Teva Pharma Drug microparticles
CA2689296C (en) * 2007-01-10 2015-11-17 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
US8063094B2 (en) 2007-02-08 2011-11-22 Boehringer Ingelheim International Gmbh Anti-cytokine heterocyclic compounds
US20080282320A1 (en) 2007-05-11 2008-11-13 Denovo Andrew Security Compliance Methodology and Tool
ES2547229T3 (en) * 2007-08-07 2015-10-02 Purdue Research Foundation Kinase inhibitors and uses thereof
US20110017340A1 (en) 2007-12-21 2011-01-27 Cabot Corporation Syntactic Foam Compositions, Pipelines Insulated with Same, and Method
BRPI0919759A2 (en) * 2008-10-20 2017-03-21 Moerae Matrix Inc adhesion treatment and prevention polypeptides
US9327008B2 (en) * 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US20110288036A1 (en) * 2010-05-24 2011-11-24 Cynthia Lander Methods for Treating or Preventing Vascular Graft Failure
SG10201604560TA (en) 2011-04-12 2016-07-28 Moerae Matrix Inc Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Also Published As

Publication number Publication date
SG194135A1 (en) 2013-11-29
AU2012242768B2 (en) 2017-10-12
EP2696888A4 (en) 2016-04-20
JP6031510B2 (en) 2016-11-24
MX359516B (en) 2018-10-01
CN104302310A (en) 2015-01-21
MX2013011771A (en) 2014-07-30
WO2012142320A3 (en) 2015-06-11
CN108014340A (en) 2018-05-11
AU2012242768A1 (en) 2013-10-24
KR20140063517A (en) 2014-05-27
EP2696888A2 (en) 2014-02-19
KR101862291B1 (en) 2018-05-29
RU2013150249A (en) 2015-05-20
HK1255005A1 (en) 2019-08-02
DK2696888T3 (en) 2019-03-25
US20120263680A1 (en) 2012-10-18
NZ616672A (en) 2016-04-29
CN111110850A (en) 2020-05-08
CA2832910A1 (en) 2012-10-18
EP2696888B1 (en) 2018-12-05
CA3042808A1 (en) 2012-10-18
CA2832910C (en) 2019-07-02
RU2620066C2 (en) 2017-05-22
WO2012142320A2 (en) 2012-10-18
ES2711670T3 (en) 2019-05-06
WO2012142320A8 (en) 2014-02-20
BR112013026313A2 (en) 2016-12-27
JP2014533235A (en) 2014-12-11
US20190022169A1 (en) 2019-01-24
BR112013026313A8 (en) 2018-01-30
US9642888B2 (en) 2017-05-09

Similar Documents

Publication Publication Date Title
SG10201604560TA (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
ZA201703305B (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
PL2672966T3 (en) Pharmaceutical composition, methods for treating and uses thereof
PL3414983T3 (en) Seed coatings, coating compositions and methods for use
SI2415763T1 (en) Pharmaceutical composition for treating or preventing glaucoma
WO2012149472A9 (en) Methods, compositions, and kits for treating and preventing neurological conditions
PT2691487E (en) Foul preventing coating composition
IL216084A0 (en) 2,4-diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation
ZA201308918B (en) Multiple myeloma treatment
SG11201501408RA (en) Zirconium pretreatment compositions containing molybdenum, associated methods for treating metal substrates, and related coated metal substrates
EP2774917A4 (en) Pharmaceutical composition for treating diabetes
EP2663671A2 (en) Metal treatment
SG11201701135WA (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
PT2770979E (en) Improved cross-linking composition delivered by iontophoresis, useful for the treatment of keratoconus
EP2673305A4 (en) Ziegler-natta catalyst composition with controlled morphology
PL2540858T3 (en) Cathodic arc deposition
SG11201501289TA (en) Preparation for preventing or treating type i diabetes
ZA201309630B (en) Film-forming composition, and use thereof for treating herpes
PT2793946T (en) Topical film-forming composition, and use thereof for treating or preventing onychophagia
HK1194983A (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
IL230582A0 (en) Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases
HK1236829A1 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
HK1240089A1 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
AU2011903969A0 (en) Compositions for treating skin conditions
PT3539540T (en) Pharmaceutical composition, methods for treating and uses thereof